The failure of conventional chemotherapy to improve overall survival rates in follicular non-Hodgkin's lymphoma (NHL) has led to the development of alternative treatment regimens. One such regimen is high-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT). In ASCT stem cells, harvested predominantly from peripheral blood, are used to repopulate the haemopoietic system after high-dose chemotherapy. Comparison of failure-free survival rates following ASCT, with those previously obtained with conventional chemotherapy, suggests a benefit for ASCT in patients who have previously responded to chemotherapy. Other factors that adversely influence the outcome of ASCT include large tumour burden and bcl-2 overexpression. Although ASCT in follicular NHL can prolong the period of remission, relapse is still common and can be caused either by contamination of the stem cell harvest with tumour cells, or regrowth of residual malignant cells not eradicated by the high-dose chemotherapy. Several strategies have been developed to reduce the rate of relapse, including in vitro purging of the stem cell product to remove tumour cells and using allogenic stem cells from HLA-matched donors with no history of malignant disease. While both these methods may have some benefit, they also have limitations. In vitro purging is labour intensive, costly and, as yet, the effect on relapse is unclear. Allogenic stem cell transplants have been associated with a reduced risk of relapse, but this is offset by increased transplantrelated mortality. The most promising strategy to reduce the rate of relapse following ASCT is in vivo purging using rituximab, a monoclonal antibody to CD20. Rituximab mobilises mechanisms to kill lymphoma cells, and causes a rapid depletion of B cells from peripheral blood. Rituximab has demonstrated good efficacy as monotherapy in patients with both aggressive and indolent lymphoma and has shown very high response rates (Ͼ95%) when used in combination with HDT.
Follicular non-Hodgkin's lymphoma (NHL) is incurable with conventional chemotherapy. While most patients achieve a remission with initial chemotherapy, the disease follows a continually relapsing pattern, with duration of remissions progressively shorter between each consecutive treatment, so that following multiple chemotherapy regimens, failure-free survival in responding patients may be less than 1 year. 1 Moreover, despite achieving clinical responses, conventional chemotherapy treatment does not appear to have any effect on overall survival in follicular NHL patients. Given the failure of conventional chemotherapy to impact significantly on outcome of follicular NHL, high-dose chemotherapy with autologous stem cell transplantation (ASCT) has been considered as an alternative approach to determine whether long-term survival can be achieved. Comparison of failure-free survival rates following ASCT with those previously obtained with conventional chemotherapy suggests a benefit for ASCT in some patients ( Figure 1 ). As with conventional chemotherapy, the outcome for patients receiving ASCT for follicular NHL is related to the number of previous chemotherapy treatments received. Patients transplanted in first remission do better than those receiving a transplant after multiple previous treatments. 2 
Factors influencing outcome of ASCT
One of the most important factors influencing ASCT outcome is the previous sensitivity of the patients to chemotherapy. Analysis of EBMT registry data from the European Group for Blood and Marrow transplantation (EBMT) indicates that patients who have previously responded to chemotherapy have similar overall and progression-free survival, whether transplanted in first remission or after chemosensitive recurrence. In contrast, in chemoresistant patients, both the progression-free and overall survival are considerably lower (Figure 2) . Thus, there appears to be little or no benefit of ASCT for patients who do not respond to chemotherapy (EBMT registry data, 2000).
Tumour burden also appears to influence the outcome of ASCT. Voso et al 3 demonstrated that patients with greater numbers of involved lymph nodes had shorter relapse-free survival following transplantation. Another important factor is the bcl-2 status of the patient following transplant. The t(14;18) chromosomal translocation leading to bcl-2 rearrangement can be detected by the sensitive polymerase chain reaction (PCR) molecular biology technique in more than two-thirds of patients with follicular NHL. 4, 5 The pres- ence of bcl-2 rearrangement may thus be used as a molecular marker of minimal residual disease. Freedman et al 6 showed, in a study of 153 patients undergoing ASCT for follicular NHL, that patients with bcl-2-negative bone marrow had markedly and significantly greater relapse-free survival than those who had detectable bcl-2 rearrangement ( Figure 3 ).
Stem cell purging in vitro
Although the use of ASCT in follicular NHL can prolong the period of remission, there is no plateau on the survival curve with patients continuing to relapse over time, therefore ASCT is not curative. Relapse is caused either by contamination of the stem cell harvest with tumour cells, or regrowth of residual malignant cells not eradicated by the high-dose chemotherapy. In order to prevent relapses caused by stem cell contamination, several investigators have attempted to purge the stem cell product of malignant cells before reinfusion into the patient. Techniques used to purge the stem cell product in vitro include the use of chemicals, drugs or monoclonal antibodies plus complement. [7] [8] [9] Alternative methods include positive selection of stem cells with CD34 antibodies. 10 All of these methods inevitably involve substantial cell losses, are labour-inten- sive and costly, and it is not clear that they offer any benefit over the use of unpurged bone marrow or peripheral blood.
11 Several studies using in vitro purged stem cells for transplantation have demonstrated longer disease-free and/or overall survival compared with historical (chemotherapy-treated) controls in relapsed follicular NHL 6, 12 and even in transformed follicular NHL. 13 However, no direct comparisons were made between purged and unpurged stem cells. The only randomised trial of unpurged vs purged stem cells in transplantation for follicular NHL has been the CUP (chemotherapy vs unpurged and purged Figure 4 Progression-free survival in patient receiving purged autologous bone marrow transplantation (ABMT), unpurged ABMT or chemotherapy for follicular NHL (the CUP trial). 14 autologous bone marrow transplantation (ABMT)) trial. In this study patients with relapsed follicular NHL were treated with three cycles of standard chemotherapy (CHOP was recommended) to achieve at least a partial response. They were then randomised to ABMT with purged or unpurged marrow, or to three cycles of the same chemotherapy without transplantation. Unfortunately, the study failed to complete recruitment, but an analysis of 140 patients that completed the trial 14 demonstrated a clear survival advantage for patients in either purged or unpurged transplanted marrow groups compared with standard chemotherapy, but insufficient numbers to show a difference between the purged and unpurged transplantation arms (Figure 4 ).
Allogeneic stem cell transplantation
Given the problems associated with tumour cell contamination of autologous stem cell harvests, allogeneic stem cell transplants have also been considered for patients with follicular NHL, as the problem of tumour cell contamination does not arise. Although no randomised trials have been performed, a number of uncontrolled studies suggest that allogeneic stem cell transplants are associated with a lower risk of relapse than autologous transplants. [15] [16] [17] However, the benefit is invariably offset by the increased incidence of transplant-related mortality in patients given allogeneic stem cells. This was demonstrated in a comparison of allogeneic transplant recipients with case-matched recipients of autologous grafts 18 (Table 1 ). Attempts to overcome the treatment toxicity of allogeneic transplantation by using chemotherapy regimens that, although intensive, do not Table 1 Overview of relapse, transplant-related mortality and eventfree survival in studies of autologous and allogeneic stem cell transplantation for follicular NHL 18 Autografts Allografts (case-matched) n = 72 n = 144 Probability of relapse 55% 12% Transplant-related mortality 4% 30% 4-year event-free survival 46% 53%
Bone Marrow Transplantation completely destroy the patient's bone marrow, are under investigation. These non-myeloablative allografting strategies rely on a graft-versus malignancy effect to prevent growth of residual lymphoma cells, while the chemotherapy provides adequate immunosuppression to prevent graft rejection. Currently, non-myeloablative allogeneic transplantation is not widely used in NHL, but is under investigation in a variety of other haematological and non-haematological malignancies.
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In vivo purging and maintenance with rituximab
One of the most promising strategies to reduce the rate of relapse following ASCT for NHL is the use of the human/mouse chimeric monoclonal antibody rituximab to eliminate malignant cells from the peripheral blood prior to stem cell harvesting (in vivo purging) and to prevent growth of residual lymphoma cells in the host during posttransplant maintenance. Rituximab acts by mobilising the host effector mechanisms to kill lymphoma cells, and causes a rapid and sustained depletion of B cells from the peripheral blood. 23 Rituximab has demonstrated good efficacy as monotherapy in patients with both indolent and aggressive lymphoma [24] [25] [26] and has shown very high response rates (Ͼ95%) when used in combination with CHOP chemotherapy. 27, 28 Initial studies indicate that rituximab does not have any adverse effects on stem cell mobilisation and is able to deplete stem cell harvests of malignant cells. 3, 29, 30 Prospective, randomised trials are underway to determine whether rituximab purging and maintenance has beneficial effects on the clinically important endpoints of disease-free and overall survival.
Conclusions
High-dose chemotherapy with ASCT has the potential to improve disease-free and overall survival in patients with follicular NHL, but new approaches are required to reduce the incidence of relapse. Currently, patients that do not respond to chemotherapy gain no benefit from ASCT. Methods of purging stem cell grafts of malignant cells in vitro are expensive and time-consuming, and it is not clear that they offer any clinical benefit. The value of newer methods such as in vivo purging will become clearer when the results of randomised trials are available.
